GCP
EIGR
GSA Capital Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-355,867
| Closed | -$109K | – | 2026 |
|
|
2023
Q3 | $109K | Buy |
355,867
+70,190
| +25% | +$21.5K | 0.01% | 1378 |
|
|
2023
Q2 | $201K | Buy |
285,677
+90,173
| +46% | +$63.4K | 0.02% | 1268 |
|
|
2023
Q1 | $175K | Buy |
195,504
+117,473
| +151% | +$105K | 0.02% | 1285 |
|
|
2022
Q4 | $92K | Buy |
+78,031
| New | +$92K | 0.01% | 1318 |
|
|
2022
Q1 | – | Sell |
-184,980
| Closed | -$960K | – | 1930 |
|
|
2021
Q4 | $960K | Buy |
184,980
+36,795
| +25% | +$191K | 0.12% | 223 |
|
|
2021
Q3 | $990K | Buy |
148,185
+68,273
| +85% | +$456K | 0.1% | 313 |
|
|
2021
Q2 | $681K | Buy |
79,912
+53,337
| +201% | +$455K | 0.08% | 442 |
|
|
2021
Q1 | $235K | Sell |
26,575
-108,961
| -80% | -$964K | 0.04% | 805 |
|
|
2020
Q4 | $1.67M | Buy |
135,536
+7,045
| +5% | +$86.6K | 0.27% | 42 |
|
|
2020
Q3 | $1.05M | Buy |
128,491
+105,689
| +464% | +$860K | 0.17% | 90 |
|
|
2020
Q2 | $219K | Buy |
+22,802
| New | +$219K | 0.12% | 298 |
|
|
2020
Q1 | – | Sell |
-12,915
| Closed | -$192K | – | 1665 |
|
|
2019
Q4 | $192K | Sell |
12,915
-6,519
| -34% | -$96.9K | 0.02% | 1268 |
|
|
2019
Q3 | $199K | Sell |
19,434
-26,485
| -58% | -$271K | 0.03% | 1165 |
|
|
2019
Q2 | $487K | Buy |
+45,919
| New | +$487K | 0.05% | 678 |
|